Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Fabbiano

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
British Journal of Haematology|April 26, 2002
Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centresLivio Pagano, Luana Fianchi, Luca Mele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2014
Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropeniaGiampaolo Bucaneve, Alessandra Micozzi, Marco Picardi, et al.
Haematologica|May 30, 2013
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohortsSabina Chiaretti, Antonella Vitale, Gianni Cazzaniga, et al.
Blood|July 21, 2010
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA GroupFrancesco Lo-Coco, Giuseppe Avvisati, Marco Vignetti, et al.
Blood|July 20, 2002
MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemiaAgostino Tafuri, Chiara Gregorj, Maria T Petrucci, et al.
Blood|March 14, 2007
ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemiaChiara Gregorj, Maria R Ricciardi, Maria T Petrucci, et al.
Blood|January 15, 2005
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocolMarco Mancini, Daniela Scappaticci, Giuseppe Cimino, et al.
American Journal of Hematology|October 23, 2016
A population-based study of chronic myeloid leukemia patients treated with imatinib in first lineFausto Castagnetti, Francesco Di Raimondo, Antonio De Vivo, et al.
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Cancer|March 22, 2025
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemiaCristina Papayannidis, Elisabetta Petracci, Patrizia Zappasodi, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|April 26, 2002
Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centresLivio Pagano, Luana Fianchi, Luca Mele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2014
Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropeniaGiampaolo Bucaneve, Alessandra Micozzi, Marco Picardi, et al.
Haematologica|May 30, 2013
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohortsSabina Chiaretti, Antonella Vitale, Gianni Cazzaniga, et al.
Blood|July 21, 2010
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA GroupFrancesco Lo-Coco, Giuseppe Avvisati, Marco Vignetti, et al.
Blood|July 20, 2002
MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemiaAgostino Tafuri, Chiara Gregorj, Maria T Petrucci, et al.
Blood|March 14, 2007
ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemiaChiara Gregorj, Maria R Ricciardi, Maria T Petrucci, et al.
Blood|January 15, 2005
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocolMarco Mancini, Daniela Scappaticci, Giuseppe Cimino, et al.
American Journal of Hematology|October 23, 2016
A population-based study of chronic myeloid leukemia patients treated with imatinib in first lineFausto Castagnetti, Francesco Di Raimondo, Antonio De Vivo, et al.
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Cancer|March 22, 2025
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemiaCristina Papayannidis, Elisabetta Petracci, Patrizia Zappasodi, et al.
Pageof 5